C4 Therapeutics, Inc (CCCC)

$6.13

-0.22

(-3.46%)▲

Live

Performance

  • $6.02
    $6.38
    $6.13
    downward going graph

    1.79%

    Downside

    Day's Volatility :5.64%

    Upside

    3.92%

    downward going graph
  • $1.06
    $11.88
    $6.13
    downward going graph

    82.71%

    Downside

    52 Weeks Volatility :91.08%

    Upside

    48.4%

    downward going graph

Returns

PeriodC4 Therapeutics, IncSector (Health Care)Index (Russel 2000)
3 Months
3.08%
3.6%
0.0%
6 Months
-7.43%
10.2%
0.0%
1 Year
312.34%
19.6%
0.0%
3 Years
-85.57%
16.8%
-23.0%

Highlights

Market Capitalization
444.5M
Book Value
$3.59
Earnings Per Share (EPS)
-1.9
Wall Street Target Price
16.14
Profit Margin
0.0%
Operating Margin TTM
-178.59%
Return On Assets TTM
-19.25%
Return On Equity TTM
-44.87%
Revenue TTM
29.4M
Revenue Per Share TTM
0.49
Quarterly Revenue Growth YOY
350.7%
Gross Profit TTM
-86.7M
EBITDA
-114.7M
Diluted Eps TTM
-1.9
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.47
EPS Estimate Next Year
-1.64
EPS Estimate Current Quarter
-0.37
EPS Estimate Next Quarter
-0.38

Analyst Recommendation

Buy
    73%Buy
    26%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for C4 Therapeutics, Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
13
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 163.3%

Current $6.13
Target $16.14

Company Financials

FY18Y/Y Change
Revenue
19.4M
-
Net Income
-15.7M
-
Net Profit Margin
-81.14%
-
FY19Y/Y Change
Revenue
21.4M
↑ 10.42%
Net Income
-34.1M
↑ 117.04%
Net Profit Margin
-159.48%
↓ 78.34%
FY20Y/Y Change
Revenue
33.2M
↑ 55.25%
Net Income
-66.3M
↑ 94.54%
Net Profit Margin
-199.83%
↓ 40.35%
FY21Y/Y Change
Revenue
45.8M
↑ 37.93%
Net Income
-86.0M
↑ 29.7%
Net Profit Margin
-187.92%
↑ 11.91%
FY22Y/Y Change
Revenue
31.1M
↓ 32.08%
Net Income
-126.5M
↑ 47.03%
Net Profit Margin
-406.8%
↓ 218.88%
FY23Y/Y Change
Revenue
20.8M
↓ 33.25%
Net Income
-132.5M
↑ 4.74%
Net Profit Margin
-638.34%
↓ 231.54%
Q1 FY23Q/Q Change
Revenue
3.8M
↑ 31.71%
Net Income
-33.9M
↓ 5.93%
Net Profit Margin
-902.85%
↑ 361.24%
Q2 FY23Q/Q Change
Revenue
2.7M
↓ 29.13%
Net Income
-35.9M
↑ 5.85%
Net Profit Margin
-1.3K%
↓ 445.57%
Q3 FY23Q/Q Change
Revenue
11.1M
↑ 315.62%
Net Income
-27.0M
↓ 24.73%
Net Profit Margin
-244.19%
↑ 1104.23%
Q4 FY23Q/Q Change
Revenue
3.3M
↓ 70.55%
Net Income
-34.8M
↑ 28.54%
Net Profit Margin
-1.1K%
↓ 821.56%
Q1 FY24Q/Q Change
Revenue
3.0M
↓ 6.81%
Net Income
-28.4M
↓ 18.4%
Net Profit Margin
-933.23%
↑ 132.52%
Q2 FY24Q/Q Change
Revenue
12.0M
↑ 295.06%
Net Income
-17.7M
↓ 37.53%
Net Profit Margin
-147.56%
↑ 785.67%
FY18Y/Y Change
Total Assets
146.5M
-
Total Liabilities
226.2M
-
FY19Y/Y Change
Total Assets
118.3M
↓ 19.27%
Total Liabilities
230.2M
↑ 1.76%
FY20Y/Y Change
Total Assets
400.1M
↑ 238.35%
Total Liabilities
119.3M
↓ 48.16%
FY21Y/Y Change
Total Assets
506.8M
↑ 26.65%
Total Liabilities
117.2M
↓ 1.83%
FY22Y/Y Change
Total Assets
430.8M
↓ 14.98%
Total Liabilities
141.6M
↑ 20.87%
FY23Y/Y Change
Total Assets
376.5M
↓ 12.62%
Total Liabilities
130.3M
↓ 7.96%
Q1 FY23Q/Q Change
Total Assets
396.0M
↓ 8.08%
Total Liabilities
133.6M
↓ 5.68%
Q2 FY23Q/Q Change
Total Assets
375.0M
↓ 5.31%
Total Liabilities
141.3M
↑ 5.79%
Q3 FY23Q/Q Change
Total Assets
333.0M
↓ 11.2%
Total Liabilities
117.0M
↓ 17.21%
Q4 FY23Q/Q Change
Total Assets
376.5M
↑ 13.04%
Total Liabilities
130.3M
↑ 11.41%
Q1 FY24Q/Q Change
Total Assets
398.4M
↑ 5.82%
Total Liabilities
140.1M
↑ 7.48%
Q2 FY24Q/Q Change
Total Assets
381.1M
↓ 4.34%
Total Liabilities
134.0M
↓ 4.32%
FY18Y/Y Change
Operating Cash Flow
-17.0M
-
Investing Cash Flow
36.9M
-
Financing Cash Flow
2.0M
-
FY19Y/Y Change
Operating Cash Flow
55.6M
↓ 427.51%
Investing Cash Flow
-1.6M
↓ 104.39%
Financing Cash Flow
244.0K
↓ 87.56%
FY20Y/Y Change
Operating Cash Flow
-67.2M
↓ 220.92%
Investing Cash Flow
-190.5M
↑ 11659.57%
Financing Cash Flow
348.9M
↑ 142904.92%
FY21Y/Y Change
Operating Cash Flow
-87.0M
↑ 29.32%
Investing Cash Flow
-189.3M
↓ 0.61%
Financing Cash Flow
171.4M
↓ 50.88%
FY22Y/Y Change
Operating Cash Flow
-105.9M
↑ 21.82%
Investing Cash Flow
58.4M
↓ 130.86%
Financing Cash Flow
1.1M
↓ 99.33%
Q1 FY23Q/Q Change
Operating Cash Flow
-33.1M
↑ 13.72%
Investing Cash Flow
15.1M
↑ 63.16%
Financing Cash Flow
-684.0K
↓ 1555.32%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.0M
↓ 42.65%
Investing Cash Flow
15.1M
↑ 0.0%
Financing Cash Flow
-746.0K
↑ 9.06%

Technicals Summary

Sell

Neutral

Buy

C4 Therapeutics, Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
C4 Therapeutics, Inc
C4 Therapeutics, Inc
2.92%
-7.43%
312.34%
-85.57%
-75.09%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
C4 Therapeutics, Inc
C4 Therapeutics, Inc
NA
NA
NA
-1.47
-0.45
-0.19
NA
3.59
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
C4 Therapeutics, Inc
C4 Therapeutics, Inc
Buy
$444.5M
-75.09%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on C4 Therapeutics, Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 3.03M → 12.00M (in $), with an average increase of 74.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -34.75M → -17.71M (in $), with an average increase of 41.3% per quarter

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 130.4%

Institutional Holdings

  • RA Capital Management, LLC

    7.04%

  • Wasatch Advisors LP

    6.99%

  • BlackRock Inc

    6.56%

  • Soleus Capital Management, L.P.

    5.84%

  • Vanguard Group Inc

    5.13%

  • COMMODORE CAPITAL LP

    4.92%

Company Information

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.

Organization
C4 Therapeutics, Inc
Employees
145
CEO
Mr. Andrew J. Hirsch M.B.A.
Industry
Health Technology

Discover More

FAQs